Charles W. Newton
Charles W. Newton's purchase track record
Charles W. Newton has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/17/2025 | LYEL | $112K | -1.6% | +27.0% | +16.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
CHRS Retains Oppenheimer to Market Legacy Biosimilar Assets. Coherus Oncology announced that it has retained Oppenheimer & Co. to market its legacy biosimilar assets. The move aims to increase visibility and potential partnerships for older products in its pipeline. The stock is currently near a long‑standing support level, which may draw attention as the company pursues these marketing efforts.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
NVAX Rallies 16% on NIH Cancer Vaccine Push Reports. Novavax shares surged 16% as part of a broader rally in vaccine stocks, driven by reports that the NIH is planning a major push for cancer vaccines. This news lifted the entire sector, with peers like Moderna and Merck also seeing significant gains. The move pushed NVAX into overbought territory, with its RSI reaching 68.6, though it remains below the average analyst target price.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Lyell Immunopharma shares fall 27% over four weeks. The stock has dropped about 27% in the past month, prompting a Yahoo article that discusses factors that could support a recovery. The piece notes the recent price weakness and points to potential catalysts that may improve sentiment. The decline leaves the share price near a key support level and the RSI is low, indicating oversold conditions.
Transaction History
| KROS | ▼ Sell | Open Market | 551 | $6K | 8/18/2026 | View on chart |
| KROS | ▼ Sell | Open Market | 550 | $6K | 6/11/2026 | View on chart |
| CHRS | ▲ Buy | Grant | 30,000 | $0 | 6/5/2026 | View on chart |
| NVAX | ▲ Buy | Option Exercise | 9,520 | $0 | 4/25/2026 | View on chart |
| KROS | ▲ Buy | Grant | 13,215 | $0 | 3/9/2026 | View on chart |
| LYEL | ▼ Sell | Open Market | 1,453 | $15K | 8/21/2025 | View on chart |
| LYEL | ▲ Buy | Grant | 8,000 | $0 | 8/20/2025 | View on chart |
| LYEL | ▼ Sell | Open Market | 136 | $1K | 8/12/2025 | View on chart |
| LYEL | ▼ Sell | Open Market | 131 | $1K | 8/11/2025 | View on chart |
| LYEL | ▲ Buy | Open Market | 200,000 | $112K | 3/17/2025 | View on chart |
| LYEL | ▲ Buy | Grant | 112,500 | $0 | 2/10/2025 | View on chart |
| LYEL | ▲ Buy | Grant | 40,000 | $0 | 2/9/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Keros Therapeutics Doses First Patient in Phase 2 Rinvatercept Trial
Keros Therapeutics has announced the dosing of the first patient in a Phase 2 clinical trial evaluating rinvatercept for Duchenne Muscular Dystrophy. This milestone marks a significant step in the development of the company's lead candidate. The stock is currently trading near its support level, with analysts setting an average price target of $19.83.
Keros Therapeutics Doses First Patient in Phase 2 Rinvatercept Trial. Keros Therapeutics has announced the dosing of the first patient in a Phase 2 clinical trial evaluating rinvatercept for Duchenne Muscular Dystrophy. This milestone marks a significant step in the development of the company's lead candidate. The stock is currently trading near its support level, with analysts setting an average price target of $19.83.